Verquvo (vericiguat) / Bayer, Merck (MSD), Chong Kun Dang - LARVOL DELTA

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Real-World Insights from Pressure Sensor Monitoring. (PubMed, J Cardiovasc Pharmacol) - "At 90 days the median loop diuretic dose (Furosemide equivalent) was 40mg [0-160], compared to 42mg [0-240] prior to vericiguat. In conclusion, vericiguat was well tolerated in stable HF patients with mild pulmonary hypertension, but no significant effect on PAP was observed. Larger studies, including patients with higher PAP, are needed to clarify its impact."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Victoria and Victor: event-driven lessons for integrating vericiguat into practice and reducing residual risk in HFrEF. (PubMed, Heart Fail Rev) - "In HF, impaired nitric-oxide (NO) signaling, reduced soluble guanylate cyclase (sGC) responsiveness/abundance, and downstream attenuation of cyclic guanosine monophosphate (cGMP) contribute to disease progression [2]. Vericiguat-an oral sGC stimulator-sensitizes sGC to endogenous NO and directly stimulates the enzyme, thereby restoring cGMP signaling in vascular smooth muscle and cardiomyocytes."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Budget Impact of Vericiguat for Treating Chronic Heart Failure in Japan. (PubMed, Circ Rep) - "Although drug and monitoring costs increased, reductions in acute care expenses helped offset these costs. Further research is needed on long-term cost-effectiveness and real-world outcomes."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Beyond the 4 Pillars: Where Does Vericiguat Stand in Contemporary HFrEF Care? (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular

Vascular diameter and responsiveness to soluble guanylate cyclase modulators: A systematic review of preclinical and clinical evidence. (PubMed, Microvasc Res) - "Current evidence supports a size-dependent pattern of vascular responsiveness to sGC modulators, but inference strength is constrained by heterogeneous methodologies and inconsistent reporting. Future work should implement standardized vessel classification, rigorous biospecimen handling, and transparent methodological documentation to clarify the clinical significance of vessel diameter in sGC-based therapy."

Journal • Preclinical • Review • Cardiovascular

Soluble guanylate cyclase stimulator vericiguat alleviates skeletal muscle injury and exercise capacity decline in ApoE-/- mice by inhibiting oxidative stress and repairing mitophagy. (PubMed, Biochem Pharmacol) - "In the mitophagy signaling pathway, the expression of p62 in skeletal muscles was decreased in vericiguat group, while the expression of PINK, Parkin, and LC3-II/I was increased. This study found that vericiguat could improve exercise capacity and mitigate skeletal muscle injury of atherosclerotic mice by repairing the impaired sGC-cGMP-PKG pathway, along with reducing skeletal muscle atrophy, inflammation and oxidative stress, and improving mitochondrial function and mitophagy."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Muscular Atrophy • APOE • IL6 • TNFA

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction (clinicaltrials.gov) - P2 | N=45 | Completed | Sponsor: Johns Hopkins University | Recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Nov 2025

Trial completion • Trial completion date • Metabolic Disorders

Phosphodiesterase 1A overexpression contributes to the progression of renal fibrosis. (PubMed, Mol Ther) - "Furthermore, vericiguat, a soluble guanylate cyclase(sGC) agonist, induced cGMP signaling and mitigated renal fibrosis in UUO mice. These findings suggest that PDE1A may play a key role in renal fibrosis. Both PDE1A inhibition or gene knockout, and sGC activation can prevent the progression of renal fibrosis."

Journal • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Nephrology • Renal Disease • TGFB1

Relief of Refractory Angina With Vericiguat. (PubMed, JACC Case Rep) - "Vericiguat may offer therapeutic benefit in refractory angina patients unresponsive to conventional therapy. Further investigation is warranted."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Metabolic Disorders

Vericiguat in heart failure with reduced ejection fraction: being confident in the face of uncertainty. (PubMed, Eur Heart J) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Therapeutic Impact of Vericiguat on Ventricular Remodeling in a Pressure-Overload Heart Failure Model. (PubMed, Life (Basel)) - "Collectively, Vericiguat mitigates pressure-overload-induced remodeling through coordinated antihypertrophic, antifibrotic, and metabolic reprogramming mechanisms. These findings support its potential as a therapeutic strategy for heart failure and warrant further clinical investigation."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology

Acute effects of vericiguat on urine excretion during baroreflex-mediated sympathetic arterial pressure regulation in male rats. (PubMed, Auton Neurosci) - "However, it maintained urine excretion at the operating point AP (55.5 ± 5.9 vs. 59.8 ± 6.9 μL·min-1·kg-1, P = 0.250) by significantly increasing the slope of the relationship between AP and normalized urine flow (0.53 ± 0.09 vs. 0.99 ± 0.14 μL·min-1·kg-1·mmHg-1, P = 0.008). The maintenance of urine excretion during vericiguat administration might be beneficial for patients with fluid retention."

Journal • Preclinical

Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies. (PubMed, Front Cardiovasc Med) - "Our findings suggest that vericiguat could be a component in the comprehensive management of heart failure with reduced ejection fraction. However, further specific investigations with longer follow-up and larger samples would enable us to resolve some of the hypotheses put forward in our study."

HEOR • Journal • Real-world evidence • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Therapeutic Potential of Vericiguat in Myocardial Ischemia/ Reperfusion Injury: Crosstalk between Heat Shock Protein 90 and Complement Activation. (PubMed, Curr Mol Med) - "HSP90 plays a crucial role in the cardioprotective effects of vericiguat, providing new insights into its mechanisms of action."

IO biomarker • Journal • Cardiovascular • Inflammation • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury • BAX • BCL2 • CDC37 • ICAM1 • IL1B • TNFA

Novel effects of vericiguat, alone and combined with high-intensity interval training, on brain function in mice with breast cancer: a histopathological and behavioral study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Histopathologically, the HIIT and vericiguat groups showed lower tumor cellularity, mitotic index, metastasis, and higher necrotic foci, compared to the BC group. In conclusion, These findings suggest a potential synergistic benefit of HIIT and vericiguat in modulating behavioral and tumor-related brain pathology in breast cancer."

Journal • Preclinical • Brain Cancer • Breast Cancer • Mood Disorders • Oncology • Psychiatry • Solid Tumor

Impact of Vericiguat on Hemodynamics of Heart Failure (clinicaltrials.gov) - P4 | N=30 | Active, not recruiting | Sponsor: University of Colorado, Denver | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure

Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction (ISPOR-EU 2025) - "Despite its clinical benefits in reducing HF hospitalizations and CV mortality, vericiguat as an adjunct to SoC for HFrEF patients in Thailand exceeds the accepted cost-effectiveness threshold of 4,342 USD/QALY gained. A price reduction of 90.2% would be necessary to achieve the current Thai WTP threshold."

Clinical • HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat: VICTORy or Defeat? (PubMed, JACC Heart Fail) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction. (PubMed, Value Health Reg Issues) - "Despite its clinical benefits in reducing HF hospitalizations and cardiovascular mortality, vericiguat as an adjunct to SoCT for patients with HFrEF in Thailand exceeds the accepted cost-effectiveness threshold of 4342 USD/QALY gained. A price reduction of 90.2% would be necessary to achieve the current Thai willingness-to-pay threshold."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Proteomic and Phosphoproteomic Profiling of Cardiac Left Ventricular Tissue from an Animal Model of Early Stage Heart Failure with Preserved Ejection Fraction after Soluble Guanylate Cyclase Stimulation (AHA 2025) - "Introduction/Background: Stimulation of soluble guanylate cyclase (sGC) represents a promising pharmacological strategy in the treatment of heart failure with reduced ejection fraction, but it has not been proved yet to be efficacious in heart failure with preserved ejection fraction (HFpEF).Research Questions/Hypothesis: Our aim was to clarify the molecular pathways involved in the cardiac effects of sGC stimulation in a preclinical model of early-stage HFpEF through the analysis of proteomic/phosphoproteomic profiles.Methods/Approach: Male obese 'Zucker fatty and spontaneously hypertensive' (ZSF1) rats (n=10) were treated at 14 weeks of age for 4 weeks with the sGC stimulator vericiguat at 3 mg/kg/p.o...Treatment increased phosphoproteins involved in pentose phosphate shunt, and small molecule, carboxylic, lipid and monocarboxyl acid catabolic pathways, while diminished those correlated with cytoskeleton-dependent cytokinesis, protein folding and organelle,..."

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Obesity

Vericiguat and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction (AHA 2025) - "In this large, real-world, propensity-matched HFrEF cohort, vericiguat initiation was associated with a 17 % relative reduction in the hazard of one-year MACE, without a statistically significant reduction in mortality or malignant ventricular arrythmia. These findings support vericiguat as an effective adjunct to guideline-directed therapy for mitigating composite cardiovascular events in HFrEF and highlight the need for prospective studies to confirm its long-term effectiveness and safety."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Pulmonary Embolism • Respiratory Diseases

Vericiguat in acute coronary syndrome with reduced ejection fraction: the EVE-ACSrEF randomized controlled trial (AHA 2025) - P4 | "On the basis of GDMT, vericiguat significantly reduces cardiovascular death or heart failure rehospitalization risks and improves left ventricular systolic function and quality of life in ACS patients with LVEF <45%. (ClinicalTrials.gov number, NCT06321094)."

Clinical • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study Evaluating the Effects of Vericiguat (BAY1021189) on Calcific Aortic Valve Stenosis (CAVS) (ChiCTR) - P1/2 | N=182 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital of Sichuan University

New P1/2 trial • Cardiovascular

A prospective multicenter clinical trial of targeted anti-inflammatory and anti-fibrotic therapy in patients with type 2 diabetes and concomitant cardiorenal disease (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

New trial • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Vericiguat in Chinese patients with heart failure and reduced ejection fraction: a real-world prospective study. (PubMed, Cardiology) - "Conclusion This prospective study is the first to report, using real-world data from a Chinese population with left ventricular ejection fraction (LVEF) <45%, that vericiguat is associated with a lower incidence of clinical endpoints, including cardiac death and hospitalization for HF. These findings align with the results of previous clinical trials."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure